Lukas Angleitner-Boubenizek

Learn More
Die Calypso Studie hat eine signifikante Verbesserung des progressionsfreien Überlebens mit PEG-liposomalem Doxorubicin (PLD) and carboplatin (P) im Vergleich zum Standardschema Paclitaxel (PCLTX)(More)
The list of authors’ names in the originally published article included only Edgar Petru, Alain Gustave Zeimet, Paul Sevelda, Michael Seifert, Michael Hubalek, Lukas Angleitner-Boubenizek, Paul(More)
The current knowledge and recommendations on the clinical use of granulocyte colony-stimulating factors (G-CSF) in gynecologic cancers including breast cancer, along with the clinical experience of(More)
Background:This is the first study investigating the safety and efficacy of the trifunctional antibody catumaxomab administered i.p. at the end of cytoreductive surgery and postoperatively prior to(More)
5082 Background: In previous studies of patients (pts) with malignant ascites due to epithelial cancers, the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) demonstrated destruction of(More)
OBJECTIVES Platinum resistance is a significant problem in patients with ovarian cancer. The aim of this phase II study was to define the response rates, the progression-free survival and the(More)